Literature DB >> 31750179

Long Term Outcomes of Intratympanic Dexamethasone in Intractable Unilateral Meniere's Disease.

Pradeep Pradhan1,2, Priti Lal3, Kanwar Sen4.   

Abstract

To evaluate the long term effect of Intratympanic dexamethasone in intractable Meniere's disease. 30 patients with refractory Meniere's disease which did not respond to the standard medical management, were treated with Intratympanic dexamethasone injections. Post treatment hearing outcome and dizziness scores were compared with the pretreatment values respectively. The mean dizziness handicap inventory (DHI) score was reduced from 91.58 (range 80-100) to be 31.00 (p = 0.00) at 3 months of treatment. With the successive follow-up periods, the mean DHI scores were reduced to 51.50, 46.6, and 50.90 at the end of, 6, 12, and 24 months (p = 0.04, 0.35, and 0.49 respectively). Again at the end of 24 months, 23.80% of patients were free of vertigo (p = 0.01). No patient had improvement in the hearing (> 10 dB) in any of the follow-up periods and 6.6% demonstrated deterioration in hearing. There were no major intraoperative or postoperative complications detected. Intratympanic injection of steroid is a safe and effective method for treating intractable Meniere's disease. Although short term improvement in the vertigo is well documented, still in 23% of the patients were found to be free of vertigo at even the end of 24 months. There was no significant improvement in hearing noticed, either in short term or in long term. © Association of Otolaryngologists of India 2018.

Entities:  

Keywords:  Clinical outcomes; Intractable Meniere’s disease; Intratympanic dexamethasone

Year:  2018        PMID: 31750179      PMCID: PMC6841822          DOI: 10.1007/s12070-018-1431-3

Source DB:  PubMed          Journal:  Indian J Otolaryngol Head Neck Surg        ISSN: 2231-3796


  15 in total

1.  Repeated courses of intratympanic dexamethasone injection are effective for intractable Meniere's disease.

Authors:  Yangming Leng; Bo Liu; Renhong Zhou; Jingjing Liu; Dongdong Liu; Su-Lin Zhang; Wei-Jia Kong
Journal:  Acta Otolaryngol       Date:  2016-09-21       Impact factor: 1.494

2.  Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application.

Authors:  L S Parnes; A H Sun; D J Freeman
Journal:  Laryngoscope       Date:  1999-07       Impact factor: 3.325

3.  Hearing results and quality of life after streptomycin/dexamethasone perfusion for Meniere's disease.

Authors:  Paul F Shea; Phyllis A Richey; Jim Y Wan; Suzanne R Stevens
Journal:  Laryngoscope       Date:  2012-01       Impact factor: 3.325

4.  Dexamethasone inner ear perfusion for the treatment of Meniere's disease: a prospective, randomized, double-blind, crossover trial.

Authors:  H Silverstein; J E Isaacson; M J Olds; P T Rowan; S Rosenberg
Journal:  Am J Otol       Date:  1998-03

5.  Effect of transtympanic injection of steroids on cochlear blood flow, auditory sensitivity, and histology in the guinea pig.

Authors:  N A Shirwany; M D Seidman; W Tang
Journal:  Am J Otol       Date:  1998-03

6.  Effects of corticosteroid, contrast medium and ATP on focal microcirculatory disorders of the cochlea.

Authors:  M Nagura; S Iwasaki; R Wu; K Mizuta; K Umemura; T Hoshino
Journal:  Eur J Pharmacol       Date:  1999-01-29       Impact factor: 4.432

Review 7.  Intratympanic steroids for inner ear disorders: a review.

Authors:  Amanda Hu; Lorne S Parnes
Journal:  Audiol Neurootol       Date:  2009-11-16       Impact factor: 1.854

8.  Longitudinal results with intratympanic dexamethasone in the treatment of Ménière's disease.

Authors:  Maria Soledad Boleas-Aguirre; Frank R Lin; Charles C Della Santina; Lloyd B Minor; John P Carey
Journal:  Otol Neurotol       Date:  2008-01       Impact factor: 2.311

9.  Hearing results of intratympanic steroid treatment of endolymphatic hydrops.

Authors:  M A Arriaga; S Goldman
Journal:  Laryngoscope       Date:  1998-11       Impact factor: 3.325

10.  Meniere's disease: evidence of an immune process.

Authors:  M D Atlas; F Chai; L Boscato
Journal:  Am J Otol       Date:  1998-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.